anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention refers to pharmaceutical industry, namely to a method for producing stable nanosuspension. Disclosed is a method of producing a stable nanosuspension containing at least one natural material, the method comprising the steps of: providing at least one natural material in which 100 % of the volume of particles has a particle size of less than 320 mcm; dispersing said at least one natural material in a solvent; milling the dispersion such that 90 % of the volume of the particles has a particle size of less than 500 nm (D&lt;500 nm), wherein the dispersion step or the grinding step includes adding a stabilizer, wherein at least one natural material is selected from a group consisting of plants, cyanobacteria, algae and fungi, and the natural material does not contain ginseng. Disclosed is nanosuspension for preparing a drug. Nanosuspension for treating or preventing a disease selected from cancer and inflammatory bowel disease, in which at least one natural material is a Brazilian agaricus (agaricus subrufescens), wherein concentration of Brazilian agar in nanosuspension is 5 % wt/wt. Application of nanosuspension for preparing a drug. Use of nanosuspension for preparing a drug for treating or preventing a disease specified in cancer and inflammatory bowel disease.EFFECT: above-described suspension is stable and effective for treating or preventing a disease specified in cancer and inflammatory bowel disease.40 cl, 22 dwg, 13 ex
PURPOSE: To dye human&#39;s hair so as to give a color tone having remarkable fastness to sweat while keeping resistance to light and washing by using 4- dihydroxy- or 4-amino-benzimidazole in the presence of p-phenylenediamine. CONSTITUTION: A compd. (A) represented by formula I (where each of R1 and R2 is H or an alkyl but at least one of them is H and R3 is OH or NH2 ) is used as a coupler for dyeing keratin fibers, especially human&#39;s hair in the presence of p-phenylenediamine (B) as a precursor of an acid dye, preferably a compd. represented by formula II (where each of R6 to R8 is H, a halogen, alkyl, hydroxyalkyl, alkoxy or carboxy, each of R4 and R5 is H, an alkyl, hydroxyalkyl, alkoxyalkyl, phenyl, etc., or R4 and R5 may form piperidino or morpholino in combination with N to which they bond). The weight ratio of B to A is &gt;=1.2, preferably &gt;=1.5. The objective hair dyeing compsn. is prepd. by adding 0.008-3.5 wt.% of the component A and 0.01-10 wt.% of the component B.
A medical closure device that is configured to be inserted into a patient&#39;s LAA (left atrial appendage) cavity comprises a closure member (1) and at least one fixing member (2), wherein the closure member (1) comprises a lid part (3) and a body part (4) one following the other in a proximal-distal direction. The lid part (3) comprises a cover portion (6) and a ring portion (7), the ring portion (7) being configured to be circumferentially disposed along the rim of an individual LAA ostium, thus sealing the LAA ostium completely. The medical closure device is designed individually for each patient. A method of manufacturing the medical closure device includes the step of forming an LAA model based on computer graphic data of the patient. The LAA model is made by 3-D printing and is an exact reproduction of the patient&#39;s LAA. The medical closure device is then preformed using the LAA model.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a slimming sheet material which is applied to the human skin, cools the skin surface, efficiently promotes blood circulation and burns and decomposes fats.  &lt;P&gt;SOLUTION: This slimming sheet material 1 is constituted of a sheet material 2 and a liniment applied to one side of the sheet material 2. The liniment 3 comprises a refreshing stimulant for providing the skin with a feeling of cold or a refreshing feeling when applied to the skin, a blood circulation promoter for improving blood circulation, a fat decomposition composition for decomposing or burning fats of the human body, a viscosity adjuster and water and/or an alcohol. Camphor is used as the refreshing stimulant. Guinea pepper essence, Citrus unshiu Mercov essence and ginger essence are used as the blood circulation promoter. Caffeine is used as the fat decomposition composition. A release sheet 4 made of polypropylene is bonded to the exposed surface of the liniment 3 of the slimming sheet material 1.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
1. Technical Result Regulation of expression of human bones morphological protein BMP-7.                  2. Essence A method for exploring low molecular weight compounds, which regulate positively or negatively the expression of human BMP-7 with reference to a reporter activity by using 5&#39; upstream region gene containing the human BMP-7 promoter and an animal cell introduced with the vector that has been connected to an appropriate reporter gene. The low molecular weight compounds and their derivatives obtained by the present method have morphogenetic activity and inhibiting activity for bone and cartilage through the expression of the human BMP-7 and are useful as preventive or therapeutic agents for cartilage and bone diseases. Furthermore, the low molecular weight compounds and their derivatives are useful as therapeutic agents for kidney diseases.         3. Field of Application Medicine.
PURPOSE:To obtain an oxytocin antagonist useful for preventing and treating premature birth, dysmenorrhea, delivery inhibition before Caesarean operation, etc., comprising a carbostyril derivative as an active ingredient. CONSTITUTION:An oxytocin antagonist comprises 1-70wt.% compound of the formula (R&lt;1&gt; is H, nitro, lower alkoxy, etc.; R is phenyl, piperidin-4-yl in which nitrogen in the ring is substitutable with alkanoyl, etc.; m is 0-3) such as 1-[1-(4- dimethylaminobenzoyl)-4-piperidinyl]-3,4-dihydrocarbostyril as an active ingredient. The oxytocin antagonist can be pharmaceutically manufactured into a dosage form such as tablet, pill, solution, suspension, emulsion, granule, capsule, injection or suppository. A dose is 0.6-50mg of the compound of the formula based on 1kg weight daily. 10-1,000mg of the compound of the formula is preferably contained in a preparation in an administration unit form. The oxytocin antagonist has inhibitory action on contraction of material smooth muscle, inhibitory action on milk release, inhibitory action on synthesis and release of prostaglandin and vasodilator action.
Systems and methods for assisting dementia patients are provided. This system also aids clinicians, family members, and caregivers as they treat and support dementia patients. In this system, patients are treated with CBD (cannabidiol)-containing medications for treatment of dementia-related symptoms. These medications may be enhanced through the inclusion of adjuvants such as terpenes, terpenoids, and anti-inflammatory compounds. On a scheduled basis, dementia-related symptoms are assessed using a variety of tests. This system also utilizes smart devices that not only assist in testing, but also in data tracking and analysis. Furthermore, this system includes the use of wearable sensors to measure patients&#39; dementia-related symptoms. These devices communicate via cloud-based services; data collected is stored in a centralized system. These data may also be accessible to researchers, drug companies, pharmacies and other health service organizations.
The invention relates to a traditional Chinese medicine for treating acute myelitis. The traditional Chinese medicine is prepared from, by weight, 18 parts of Radix Ranunculi Ternati, 12 parts of Airpotato Yam Rhizome, 10 parts of Rhizoma Curcumae, 15 parts of Herb of Dracocephalum heterophyllum Benth., 10 parts of Herb of Pilosella-leaved Drymoglossum, 30 parts of Fruit of Emblic Leafflower, 12 parts of Artemisia capillaries, 12 parts of Wrightia. tomentosa Roem. &amp; Sch. and 12 parts of Radix Curcumae Aromaticae. Clinic experiments prove that the acute myelitis can be safely and effectively treated by using the traditional Chinese medicine.
A device for insertion into the vagina delivers a flowable therapeutic formulation to the vaginal surfaces. The device comprises a reservoir 16 having a forward end for placement proximate a user&#39;s cervix, a trailing end facing opposite the cervix, and a peripheral edge. The reservoir 16 also comprises a non-woven fibrous material throughout. The device also comprises a flowable therapeutic formulation contained within and completely saturating the reservoir 16 throughout. The non-woven fibrous material is hydrophobic relative to the flowable therapeutic formulation. The device further comprises a layer 1255 affixed proximate the peripheral edge of and substantially parallel to the reservoir 16. A finger pocket 39 is formed between the layer 1255 and the reservoir 16 proximate the trailing end. The reservoir 16 and the flowable therapeutic formulation create capillary forces causing the flowable therapeutic formulation to migrate to the outer surfaces of the reservoir 16.
A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject&#39;s immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
&lt;P&gt;PROBLEM TO BE SOLVED: To paste medical images as well as information on nodes in the image on an interpretation report.  &lt;P&gt;SOLUTION: When target image key information, positional information of the node in the target image, and information on an operation type for instructing to &#34;paste an image on a report&#34; are supplied to an image management part 2b from an input management part 2a, the image management part reads out the target image from an image storing part 2c and generates an image for pasting by duplicating it. The image management part 2b supplies the positional information of the nodes in the target image to an image analyzing part 2e to have the dimensions or the like of the node analyzed and receives node information being a result of the analysis. The image management part 2b supplies the generated image for pasting and the node information received from the image analyzing part 2e to an output management part 2f. The output management part 2f pastes the image for pasting and the node information supplied from the image management part 2b on a prescribed position on a screen for creating the interpretation report which is displayed on a monitor 3.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject substance comprising deferoxamine and effective for the therapy of wounds. SOLUTION: This substance for treating wounds comprises deferoxamine of formula I (R&#39; is a group of formula II) or its salt. A wound-treating medicine contains the wound-treating substance in an amount of 10&lt;-5&gt; to 50wt.% as an active ingredient. The compound of formula I is obtained by culturing a deferoxamine-producing strain belonging to the genus Streptomyces or by a synthetic method. The medicine is administered at a daily dose of 10ng to 1g/Kg as the wound-treating substance with one to four portions. Although the wounds of surface tissues are generally refractory, and can sufficiently not be cured with existing medicines, the medicine containing the compound of formula I is highly effective.
Automating medical practice workflow and billing presents difficulties in many aspects, especially in interacting with the workflow, other healthcare providers, and within the constraints of payor requirements. Disclosed are methods, systems, software and means for automatically providing additional documentation to reconcile a billing claim. In one implementation, there is a computerized method for automatically providing additional documentation to reconcile a billing claim. The method, typically executed in software, includes providing a billing claim based on a patient&#39;s workflow, the billing claim typically associated with an a payor such as an insurance provider. The method also involves automatically identifying a document associated with the billing claim based on the patient&#39;s workflow. Typically the claim is submitted to the payor and the document is sent to the payor as well, the communications with the payor occurring over a communications network.
PURPOSE:To obtain the title sol which has never been obtained conventionally by heating an aqueous suspension containing zirconium hydroxide to give an aqueous mixture containing crystallized zirconia, adding an acid to the aqueous mixture, peptizing the mixture and dehydrating the zirconia sol. CONSTITUTION:An aqueous suspension containing zirconium hydroxide is heated and maintained at &gt;=80 deg.C until zirconia is sufficiently crystallized to give an aqueous mixture containing crystallized zirconia. Then the aqueous mixture is blended with an acid and zirconia is peptized to give sol of fine crystallized zirconia dispersed in an aqueous solvent. Then the acid is removed from the sol. Removal of the acid is not especially restricted and, for example, removal of low-boiling acid by heating, adjustment of pH&gt;=5.0 with anion exchange resin, etc., may be cited as the removal of acid. Consequently, weakly acidic crystallized zirconia-based sol having pH of weak acidity, excellent dispersibility and dispersion stability is obtained.
The present invention relates to methods for disinfecting or decontaminating a material or for preventing an infection or contamination of a material. The invention further relates to compositions which are suitable for disinfecting a material or for preventing an infection or contamination of a material and to uses of such compositions. The invention further relates to a medical use of chitosan and to a pharmaceutical composition comprising the chitosan. The invention further relates to a method of treating a microbial infection and to an aqueous solution comprising chitosan. The invention moreover relates to a chitosan or a pharmaceutical composition comprising a chitosan for an epithelial cell growth stimulating treatment of a patient&#39;s tissue and to a method of stimulating the growth of epithelial cells. The invention also relates to a tissue dressing material.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating multi-drug resistant cell.  &lt;P&gt;SOLUTION: The pharmaceutical composition includes a competing agent of hyaluronan interaction with an effective dosage in order to reduce the cellular tolerance against a pharmacologic agent. As the competing agent of hyaluronan interaction, hyaluronan binding protein is exemplified, more specifically hyaluronidase which digests a hyaluronan polymer to a hyaluronan oligomer is cited. The composition includes a competing agent (CHI) of HA interaction occurring in vivo. For example, CHI is a ligand of an HA receptor or is a decoy capable of uniting to HA.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new whitefly ecdysone receptor polypeptide.  &lt;P&gt;SOLUTION: The nucleic acid encodes a whitefly ecdysone receptor polypeptide. The vector comprises the same. The method for modulating gene expression in an ecdysone receptor-based gene expression modulation system is provided. The method for identifying molecules that modulate whitefly ecdysone receptor activity is provided. The uses thereof are provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. We have found that giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone&#39;s negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. Therefore, the methadone regimen is replaced with morphine prior to noribogaine treatment.
Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21&lt;HIL&gt;&lt;ras&lt;/SP&gt;&lt;PDAT&gt;. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21&lt;HIL&gt;&lt;ras&lt;/SP&gt;&lt;PDAT&gt;. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme. The most potent inhibitors are ones in which phenylalanine occurs at the third position of a tetrapeptide whose amino terminus is cysteine.&lt;/PTEXT&gt;
FIELD: molecular biology, veterinary science. SUBSTANCE: invention relates to method that can be used for detection of cattle viral diarrhea. Method involves synthesis of oligonucleotide primers 5&#39;-TAG-ATT-CCA-GAC-CGA-CCC-3&#39; and 5&#39;-GGA-AGG-GAT-ACA-ACG-GGC-3&#39; and synthesis of complementary DNA on DNA matrix. Then amplification of synthesized DNA is carried out by method of polymerase chain reaction and polymerase chain reaction products size is analyzed. Proposed method ensures to differentiate cattle viral diarrhea virus from the close-related classical porcine plague virus. EFFECT: improved method of virus detection. 1 tbl, 1 ex
The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium,  Haemophilus influenzae.  The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of  H. influenzae  enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may be affected by an interaction between environmental conditions (i.e., for example, oxygen tension) and genetic regulation of precursor biosynthetic pathway activity. LOS-PC epitope display increases under microaerobic conditions and decreases under aerobic conditions. This is consisent with a bacteria&#39;s propensity to initiate pathogensis under low oxygen conditions. Pathogenesis may be prevented by disrupting the role of the putative  H. influenzae  homologue of CsrA, that downregulates galU expression. Disrupting CsrA repression of galU expression resulted in increased LOS-PC epitope display.
214,238. Squibb &amp; Sons, E. R., (Assignees of Nitardy, F. W.). April 9, 1923, [Convention date]. Void [Published under Sect. 91 of the Act]. Preserving cod-liver oil &amp;c.-Food substances rich in vitamine A, such as cod-liver oil, are packed in vessels, the air in which is replaced by inert gas such as carbon dioxide or nitrogen to prevent the destruction of the vitamine by oxidation. To ensure the complete expulsion of air a drum may be completely filled with oil, a portion of which is then expelled by the inert gas, the drum being then sealed. The oil may be filtered in an atmosphere of inert gas, and the bottles in which it is sold filled with such gas, particularly carbon dioxide, above the oil.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide foods or cosmetics which retain or improve the excellent food effect and functions of mushrooms as well as show excellent quality, safety, good taste and food feeling.  &lt;P&gt;SOLUTION: Raw or dried fruit bodies and/or mycelia, when necessary, finely crushed, are combined with one or more kinds of lactobacilli and yeasts and the mixture is fermented. The fermentation mixture, its dried product or their powdery products are used as foods or the powdery product is added to foods or cosmetics and the mixtures are processed to foods or cosmetics. As fruits and mycelia of mushrooms are fermented together with lactobacilli and yeasts, the resultant fermentation products or their processed products have the actions and effects of the mushrooms as well as the effects of the culture mixture of microorganisms whereby the complex effects are developed. Consequently, foods and cosmetics having excellent quality, safety and effects are obtained.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The invention provides a preparation of tumor cell lines containing an exogenous gene encoding a polypeptide that potentiates the immune response to the tumor, for example, interleukin-2. The invention includes methods for cancer therapy by immunization with the immunopotentiating tumor cell. The invention also provides methodology whereby one can selectively ablate in vitro and in vivo genetically altered cells. A preferred embodiment of this aspect of the invention includes a cell containing a first exogenous gene encoding an immunopotentiating polypeptide and a second exogenous gene encoding a &#34;lethal&#34; or &#34;suicide&#34; polypeptide, preferably under the control of an inducible promoter. Introduction of the second exogenous gene confers the ability to selectively kill the tumor cell by inducing a promoter in operative linkage to the gene encoding the lethal polypeptide to initiate transcription of the polypeptide. Diphtheria toxin or the thymidine kinase of Herpes simplex virus are exemplary lethal genes. An exemplary promoter employed is the 6-16 promoter, which is inducible with low levels of interferon. Methods for using the cells in cancer therapy are also provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new method for protecting a cat from the infection of a wide range of FIV (feline immunodeficiency virus) strains by using a various subtype FIV vaccine.  &lt;P&gt;SOLUTION: This various subtype FIV vaccine containing any of the whole of acellular virus or viral-infected cell strains is described. Also the method for vaccinating the cat by the vaccine composition is described. Thus, the cat vaccinated according to the above method and composition exhibits defensive humoral and cellular immunological responses against the FIV in the case of being challenged by an allogenic or a xenogeneic FIV strain. The disclosed is related to a new Felidae cell line which is easily infective with the FIV and the method for using the same.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT